论文部分内容阅读
据美国巴尔的摩的马利兰大学肿瘤中心Richard Leavitt及其助手称,通过重组DNA技术产生的人类干扰素,在“轻度”晚期非何杰金氏淋巴瘤(NHL)中有缓解作用,而其他所有可采用的治疗方法对NHL均无效。 Leavitt在第二届国际恶性淋巴瘤会议的专题讨论会上宣称,12名患NHL的病人用加强化疗和放疗失败后,曾用重组α-2干扰素治疗,3人已获得部分缓解。全部病人每周3次按1,000万单位/m~2剂量接受干扰素,至少6个月,或在已获得最大疗效后再增加2个月的治疗。一名患Ⅲ期NHL的病人经治疗2个月,获
According to Richard Leavitt and his assistant at the University of Maryland Medical Center in Baltimore, human interferon produced by recombinant DNA technology has a mitigating effect in “mild” advanced non-Hodgkin’s lymphoma (NHL), and all others can The treatment used did not work for NHL. Leavitt claimed at the second symposium of the International Malignant Lymphoma Conference that 12 patients with NHL had been treated with recombinant alpha-2 interferon after the failure of enhanced chemotherapy and radiotherapy, and 3 had achieved partial remission. All patients received interferon at a dose of 10 million units/m 2 3 times per week for at least 6 months, or 2 months after the maximum effect was achieved. A patient suffering from stage III NHL was treated for 2 months and obtained